Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Authors :: Jing‐Wei Li
Clare Arnott
Hiddo J. L. Heerspink
Qiang Li MBiostat
Christopher P. Cannon
David C. Wheeler
David M. Charytan
Jennifer Barraclough
Gemma A. Figtree
Rajiv Agarwal
George Bakris
Dick de Zeeuw
Tom Greene
Adeera Levin
Carol Pollock
Hong Zhang
Bernard Zinman
Kenneth W. Mahaffey
Vlado Perkovic
Bruce Neal
Meg J. Jardine
Source :: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 16 (2022)
Publication Year :: 2022
Publisher :: Wiley, 2022.
Abstract: Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In this post hoc analysis, we evaluated the effect of canagliflozin on total (first and recurrent) cardiovascular events. Methods and Results The CREDENCE trial compared canagliflozin or matching placebo in 4401 patients with type 2 diabetes, albuminuria, and estimated glomerular filtration rate of 30 to

Subjects :: canagliflozin
chronic kidney disease
diabetes
recurrent cardiovascular event
Diseases of the circulatory (Cardiovascular) system
RC666-701

Language :: English
ISSN :: 20479980
Volume :: 11
Issue :: 16
Database :: Directory of Open Access Journals
Journal :: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Publication Type :: Academic Journal
Accession number :: edsdoj.46cbfff7ef724eea8154c25524ea230a
Document Type :: article
Full Text :: https://doi.org/10.1161/JAHA.121.025045

Full Text Access

Tools